Ironwood Pharmaceuticals (IRWD) Enterprise Value (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Enterprise Value data on file, last reported at -$220.5 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 103.23% year-over-year to -$220.5 million; the trailing twelve-month figure through Mar 2026 stood at -$220.5 million (down 103.23% YoY), and the FY2025 full-year result was -$215.5 million, down 143.29% from the prior year.
• Enterprise Value retreated to -$220.5 million in Q1 2026, from -$215.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$88.2 million in Q3 2024 to a low of -$741.6 million in Q1 2023.
• A 5-year average of -$272.9 million and a median of -$140.4 million in 2025 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value soared 85.98% in 2023 and plunged 143.29% in 2025, its largest moves.
• Tracing IRWD's Enterprise Value over 5 years: stood at -$657.5 million in 2022, then surged by 85.98% to -$92.2 million in 2023, then climbed by 3.9% to -$88.6 million in 2024, then slumped by 143.29% to -$215.5 million in 2025, then slipped by 2.33% to -$220.5 million in 2026.
• Business Quant data shows IRWD's Enterprise Value at -$220.5 million in Q1 2026, -$215.5 million in Q4 2025, and -$140.4 million in Q3 2025.